Smaller biotechs hit as Shire cuts bait on experimental drugs

Share this article:

Amicus Therapeutics announced a work-force reduction of about 20%, or 26 employees, as a part of a corporate restructuring after a commercialization deal with Shire soured.

Shire had licensed compounds in development for Fabry disease, Gaucher disease and Popme disease from the company in November 2007.

Shire also said it will terminate its collaboration with Alba Therapeutics on an experimental drug for celiac disease. Shire acquired rights to the drug, larazotide cetate, outside of the US and Japan at the end of 2007. 

As for Amicus, the biotech said reductions will occur across all levels and organizations within the company, and it is terminating relationships with contractors.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.